GPhC urges pharmacies to have valproate safeguards in place

Latest

GPhC urges pharmacies to have valproate safeguards in place

In Latest

The General Pharmaceutical Council has reminded pharmacy teams to ensure they have safeguards in place when prescribing valproate to patients.

The regulator said pharmacies needed to make sure women and girls have accurate information about the risks of birth defects as a result of taking the medicine which is primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches.

Pharmacies have been urged not to supply valproate to any patient who is able to have children unless there is a pregnancy prevention programme in place.

The GPhC said pharmacies should give women and girls a patient card each time they dispense valproate which must be supplied with a patient information leaflet and a warning on the container if it has been repackaged.

Pharmacy teams were also urged to remind patients about the risks of taking the medicine during pregnancy and the need for “highly effective contraception” as well as the importance of an “annual specialist review.” Patients must be asked if they have had the patient guide.

“You must make sure that the patient label is not placed over the warning labels or warning sticker on the box. Women taking valproate have shared with us examples of where this has happened,” the GPhC said.

“When patients are visiting pharmacies for pregnancy tests or emergency hormonal contraception, remember to ask them about any medications they are taking so you can provide further advice if their medicines are teratogenic.”

According to NHS Digital’s medicines in pregnancy registry, 47,532 females up to the age of 54 were prescribed one or more prescriptions for valproate in one or more months between April 2018 and September 2020, while 180 females were prescribed valproate whilst pregnant during that period.

The data also revealed that 238 females stopped receiving prescriptions for the medicine before their pregnancy.

Earlier this month, NHS England and Improvement sent a letter to all women and girls aged 12 to 55 who are taking valproate warning them of the safeguards that need to be taken. The GPhC said it shared the letter with pharmacy professionals.

Record my learning outcomes

Latest

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

Loading...

Recommended Learning

bookmark icon off
Sponsored education

Sore throat treatment update

Update your knowledge on treating sore throat without antibiotics with this short, interactive module.

10 Min Module

bookmark icon off
Sponsored education

Oral rehydration: a pharmacy guide

Understand the important role oral rehydration products play in helping prevent dehydration after illness

5 Min Module

bookmark icon off
Videos

Supporting daily digestive health

Learn about the crucial role of gut bacteria and how a healthy microbiome can support daily digestive health

2 Min Module

bookmark icon off
Sponsored education

VIAGRA CONNECT®: eLearning for the pharmacy team

This module will help the pharmacy team to understand erectile dysfunction and its causes, and supply Viagra Connect to male customers affected by it, where appropriate

10 Min Module

Sponsored education

Acute diarrhoea: effective symptom management

This module busts the myths surrounding diarrhoea treatments and explores the products available OTC so you can recommend the right treatment.

10 Min Module

bookmark icon off
Sponsored education

Next-level parasite protection for dogs

Explore the FRONTLINE Tri-Act® active pack to learn about next-level parasite protection for dogs.

10 Min Module